|1.||Wallace, John L: 7 articles (06/2015 - 03/2010)|
|2.||Flannigan, Kyle L: 2 articles (06/2015 - 09/2014)|
|3.||Blackler, Rory W: 2 articles (06/2015 - 09/2014)|
|4.||Cuzzocrea, Salvatore: 2 articles (01/2014 - 11/2013)|
|5.||Campolo, Michela: 2 articles (01/2014 - 11/2013)|
|6.||Ahmad, Akbar: 2 articles (01/2014 - 11/2013)|
|7.||Di Paola, Rosanna: 2 articles (01/2014 - 11/2013)|
|8.||Esposito, Emanuela: 2 articles (01/2014 - 11/2013)|
|9.||De Palma, Giada: 1 article (06/2015)|
|10.||Manko, Anna: 1 article (06/2015)|
01/01/2014 - "These data demonstrate that ATB-346 can be efficacious in a TBI animal model by reducing the secondary inflammation and tissue injury. "
01/01/2014 - "ATB-346 also significantly reduced the severity of inflammation and restored neurotrophic factors that characterized the secondary events of TBI. "
06/15/2015 - "Naproxen caused significant intestinal damage and inflammation, whereas ATB-346 did not. "
03/01/2010 - "The ability of ATB-346 to inhibit cyclooxygenase-1 and 2 and to reduce inflammation in vivo was also evaluated. "
11/01/2013 - "ATB-346 also significantly reduced the severity of inflammation (proinflammatory cytokines, apoptosis of neural tissue, and nitrosative stress) that characterized the secondary effects of SCI. Again, the effects of ATB-346 were superior to those of naproxen for several parameters. "
|2.||Brain Edema (Cerebral Edema)
04/01/2015 - "Male Wistar rats (n=48) were randomly assigned to four main groups: normal control, untreated arthritis, Naproxen and ATB-346 treated groups. "
01/01/2013 - "In addition, released H2S may account for the absence of deleterious gastric effects, thus making of ATB-346 a potentially useful therapeutic alternative to traditional naproxen for treatment of patients with arthritis."
03/01/2010 - "ATB-346 was as effective as naproxen in adjuvant-induced arthritis in rats, with a more rapid onset of activity. "
04/01/2015 - "Therefore, this study was undertaken to evaluate the effects of ATB-346 as a novel H2S-releasing naproxen compared to naproxen, as a traditional non-steroidal anti-inflammatory drug on zymosan induced mono-arthritis in rats. "
|4.||Spinal Cord Injuries (Spinal Cord Injury)
11/01/2013 - "In the current study, we evaluated the potential beneficial effects of ATB-346 [2-(6-methoxynapthalen- 2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester], an H2S-releasing derivative of naproxen, in a murine model of spinal cord injury (SCI). "
01/01/2014 - "We recently reported that administration of ATB-346 (2-(6-methoxynapthalen- 2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester), a hydrogen sulfide-releasing cyclooxygenase inhibitor, showed marked beneficial effects in an animal model of spinal cord injury, significantly enhancing recovery of motor function and reducing the secondary inflammation and tissue injury. "
|5.||Brain Injuries (Brain Injury)
01/01/2014 - "Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice."
01/01/2014 - "In these studies, TBI was induced in mice by CCI and mice were orally administered ATB-346, naproxen (both at 30 μmol/kg) or vehicle (dimethylsulfoxide:1% carboxymethylcellulose [5:95] suspension) one and six hours after brain trauma and once daily for 10 days. "
|3.||Nerve Growth Factors (Neurotrophins)
|5.||Dimethyl Sulfoxide (DMSO)
|6.||Carboxymethylcellulose Sodium (Polycell)
|7.||propionic acid (potassium propionate)
|8.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|9.||Hydrogen Sulfide (Sulfide, Hydrogen)